J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Subscribe To Our Newsletter & Stay Updated